Rankings
▼
Calendar
URGN
UroGen Pharma Ltd.
$927M
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$18M
+11.9% YoY
Gross Profit
$16M
87.5% margin
Operating Income
-$20M
-112.1% margin
Net Income
-$29M
-159.6% margin
EPS (Diluted)
$-1.22
QoQ Revenue Growth
+12.4%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$21M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$136M
Total Liabilities
$225M
Stockholders' Equity
-$89M
Cash & Equivalents
$55M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$18M
$16M
+11.9%
Gross Profit
$16M
$15M
+8.5%
Operating Income
-$20M
-$20M
-1.8%
Net Income
-$29M
-$28M
-1.5%
Revenue Segments
Jelmyto
$18M
100%
← FY 2022
All Quarters
Q1 2023 →
URGN Q4 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena